Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care-Reference-Cited by-同舟云学术

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Published:2017-12 Issue:12 Volume:7 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Nazha Aziz,Sekeres Mikkael A.,Komrokji Rami,Steensma David P.,Kantarjian Hagop,Roboz Gail,Fenaux Pierre,Prebet Thomas^ORCID,Azarnia Nozar,Zbyszewski Patrick S.,Fruchtman Steven M.,Santini Valeria,Silverman Lewis R.,Platzbecker Uwe,Garcia-Manero Guillermo

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-017-0018-7.pdf

Reference8 articles.

1. Fenaux, P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet. Oncol. 10, 223–232 (2009).

2. Lubbert, M. et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J. Clin. Oncol. 29, 1987–1996 (2011).

3. Prebet, T. et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J. Clin. Oncol. 29, 3322–3327 (2011).

4. Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088 (1997).

5. Greenberg, P. L. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454–2465 (2012).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents;Annals of Hematology;2023-12-01

2. Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na);Pharmaceutics;2023-04-13

3. Expanding the immune armoury against myelodysplastic syndrome;British Journal of Haematology;2021-08-02

4. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice;Cancer;2021-03-19

5. Prognostic Risk Factors in Myelodysplastic Syndromes in Adults;Гематология. Трансфузиология. Восточная Европа;2020-11-10